Erasca reports RAS cancer drug data after legal threat from Revolutionnews2026-04-27T20:01:10+00:00April 27th, 2026|Endpoints News|
Revolution Medicines threatens to sue Erasca over patent, efficacy claimsnews2026-04-27T18:17:42+00:00April 27th, 2026|Endpoints News|
Utah doctors demand suspension of Doctronic AI programnews2026-04-27T17:42:11+00:00April 27th, 2026|Endpoints News|
Q&A: Intellia CEO talks first Phase 3 CRISPR readout and what’s nextnews2026-04-27T15:30:00+00:00April 27th, 2026|Endpoints News|
Thermo Fisher sells microbiology biz; Ligand to buy XOMAnews2026-04-27T15:17:23+00:00April 27th, 2026|Endpoints News|
Oruka posts Phase 2 win in psoriasis, hoping to compete with Skyrizinews2026-04-27T14:19:00+00:00April 27th, 2026|Endpoints News|
Lilly announces a new cancer deal, paying Ajax up to $2.3B for JAK inhibitornews2026-04-27T12:36:19+00:00April 27th, 2026|Endpoints News|
Compass Therapeutics unveils key secondary endpoint results from pivotal biliary tract cancer trialnews2026-04-27T11:30:28+00:00April 27th, 2026|Endpoints News|
Intellia’s in vivo CRISPR therapy first to succeed in Phase 3news2026-04-27T11:01:29+00:00April 27th, 2026|Endpoints News|
Veradermics wins at growing hair with oral Rogaine in first key test as a public companynews2026-04-27T11:00:29+00:00April 27th, 2026|Endpoints News|
